Press releases

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.543 billion during the first quarter of 2020. This represents growth of 2.0 percent on a reported basis, 3.2 percent on an...

Boston Scientific Corporation (NYSE: BSX) has signed a virtual power purchase agreement (VPPA) that represents the largest step the company has taken to achieve its goal of global carbon neutral...

Boston Scientific Corporation (NYSE: BSX) today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held exclusively in a virtual meeting format at the previously...

The COVID-19 pandemic has brought unprecedented challenges upon the global community and the many healthcare providers who are caring for patients. During this time of concern and disruption,...

Boston Scientific Corporation (NYSE: BSX) will participate in three upcoming investor conferences. On February 27, 2020, Susie Lisa, vice president, Investor Relations, will participate in a...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.905 billion during the fourth quarter of 2019. This represents growth of 13.4 percent on a reported basis, 14.1 percent on an...

Boston Scientific Corporation (NYSE: BSX) generated sales, based upon preliminary unaudited financial information, of approximately $2.90 billion during the fourth quarter of 2019. This represents...

Boston Scientific Corporation (NYSE: BSX) will participate in the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 in San Francisco, California. Mike Mahoney, chairman...

Boston Scientific Corporation (NYSE: BSX) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the EXALT™ Model D Single-Use Duodenoscope for use in endoscopic retrograde...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in two investor conferences this December. On Wednesday, December 4, 2019, Susie Lisa, vice president, Investor Relations, and...

Boston Scientific Corporation (NYSE: BSX) (the "Company") completed a public offering of €900.0 million aggregate principal amount of 0.625% Senior Notes due 2027 (the "Notes"). The Company has...

Boston Scientific Corporation (the "Company") (NYSE: BSX) announced the pricing of a public offering of €900,000,000 aggregate principal amount of its 0.625% notes due 2027, under the Company's...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Today, Boston Scientific (NYSE: BSX) announced positive data for two devices within the peripheral drug-eluting product portfolio during separate late-breaking clinical trial presentations at...

Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate...

Boston Scientific Corporation (NYSE: BSX) will participate in four conferences, including one industry conference and three investor conferences, this month. On November 5, 2019, Jeff Mirviss,...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.707 billion during the third quarter of 2019. This represents growth of 13.1 percent on a reported basis, 14.2 percent on an...

Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $1.0 billion aggregate principal amount (the...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2019 on Wednesday, October...

Boston Scientific (NYSE: BSX) has announced primary endpoint results from the EVOLVE Short DAPT clinical trial, the first prospective study initiated in the U.S. to examine the safety of a...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the...

Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2019 Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019 in Boston. Mike Mahoney, chairman and...

Boston Scientific Corporation (NYSE:BSX) announced the U.S. Food and Drug Administration (FDA) approval of its ImageReady™ MRI labeling for the Vercise Gevia™ Deep Brain Stimulation (DBS)...

Boston Scientific Corporation (NYSE: BSX) today announced the completion of its acquisition of BTG plc. (LSE: BTG) pursuant to the previously announced scheme of arrangement. BTG develops and...

On August 7, 2019, the U.S. Food and Drug Administration (FDA) published guidance to physicians about the benefit-risk profile of peripheral paclitaxel devices intended for the treatment of...

Boston Scientific Corporation (NYSE: BSX) will participate in the 39th Annual Canaccord Genuity Growth Conference on Thursday, August 8, 2019 in Boston. Susie Lisa, vice president, Investor...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.631 billion during the second quarter of 2019. This represents growth of 5.6 percent on a reported basis, 8.0 percent on an...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2019 on Wednesday, July 24,...

Boston Scientific Corporation (NYSE: BSX) is hosting a meeting with the investment community today in New York City to review its business and long-term growth strategies. The company is...

We appreciate the perspectives shared about the safety and benefits of peripheral paclitaxel devices during the FDA’s meeting of the Circulatory System Devices Panel. Boston Scientific shares...

On June 19-20, 2019, the U.S. Food and Drug Administration (FDA) held a meeting of the Circulatory System Devices Panel about peripheral devices with paclitaxel. Although data on the Boston...

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Vertiflex, Inc., a privately-held company that developed and commercialized the Superion® Indirect...

Boston Scientific Corporation (NYSE: BSX) has initiated the OPTION trial to compare safety and effectiveness of the next-generation WATCHMAN FLX™ left atrial appendage closure (LAAC) platform to...

Boston Scientific Corporation (NYSE: BSX) will participate in Bernstein's 35th Annual Strategic Decisions Conference on Wednesday, May 29, 2019 in New York City. Mike Mahoney, chairman and chief...

Boston Scientific (NYSE: BSX) today announced acute results from the UNTOUCHED study evaluating safety and efficacy of the EMBLEM™ Subcutaneous Implantable Defibrillator (S-ICD) System for...

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Vertiflex, Inc., a privately-held company which has developed and commercialized the...

Boston Scientific Corporation (NYSE: BSX) will participate in the 2019 UBS Global Healthcare Conference on Tuesday, May 21, 2019 in New York City. Art Butcher, senior vice president and president,...

Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive...

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Heart Rhythm Scientific Sessions, in San...

Boston Scientific Corporation (NYSE: BSX) will participate in the Bank of America Merrill Lynch Healthcare Conference 2019 on Wednesday, May 15, 2019 in Las Vegas. Dan Brennan, executive vice...

Boston Scientific Corporation (NYSE: BSX) generated sales of $2.493 billion during the first quarter of 2019. This represents growth of 4.8 percent on a reported basis, 7.8 percent on an...

Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration (FDA) approval for the LOTUS Edge™ Aortic Valve System. Delivered via a...

On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse (POP) to stop selling and...

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2019 on Wednesday, April 24,...

Boston Scientific Corporation (NYSE: BSX) announced data from the AF-FICIENT I study during a late-breaking clinical trial session today at EHRA 2019, the annual congress of the European Heart...

Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the next generation WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device in

Boston Scientific Corporation (NYSE: BSX) today announced key data that will be featured at EHRA 2019, the annual congress of the European Heart Rhythm Association (EHRA) in Lisbon, Portugal, on...

Solutions for nutrition support and early detection of respiratory issues win and place at Connected Patient Challenge competition focused on chronic conditions MARLBOROUGH, Mass., February 28,...

Boston Scientific Corporation (NYSE: BSX) will participate in the Cowen and Company 39th Annual Healthcare Conference on Wednesday, March 13, 2019 in Boston. Dan Brennan, executive vice president...

Boston Scientific Corporation (NYSE: BSX) completed a public offering of $4.3 billion aggregate principal amount of its senior notes. The public offering consists of $850 million of 3.450% notes...